Patients with generalized myasthenia gravis who responded best to efgartigimod were not the ones with the biggest drop in ...

HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they ...

Sujith Ramachandran, PhD, associate director of Trinity Life Sciences, grouped access barriers into 3 buckets: upfront ...

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes ...

The number of approvals is really only 1 piece of the pie,” said Nicole A. Caffiero, PharmD, MBA, BCACP, senior clinical ...

Frailty, but not HIV serostatus, is tied to more severe lower urinary tract symptoms in adults with and at risk for HIV, a ...

T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access ...

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower ...